Home Cart Sign in  
Chemical Structure| 58-32-2 Chemical Structure| 58-32-2

Structure of Dipyridamole
CAS No.: 58-32-2

Chemical Structure| 58-32-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Dipyridamole is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.

Synonyms: NSC 515776; NSC 619103; Dipyridamol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Dipyridamole

CAS No. :58-32-2
Formula : C24H40N8O4
M.W : 504.63
SMILES Code : OCCN(CCO)C1=NC(N2CCCCC2)=C(N=C(N(CCO)CCO)N=C3N4CCCCC4)C3=N1
Synonyms :
NSC 515776; NSC 619103; Dipyridamol
MDL No. :MFCD00010555
InChI Key :IZEKFCXSFNUWAM-UHFFFAOYSA-N
Pubchem ID :3108

Safety of Dipyridamole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • PDE

In Vitro:

Cell Line
Concentration Treated Time Description References
BEAS-2B cells 10 μM 8 hours Validate the anti-ferroptotic effect of Dipyridamole in bronchial epithelial cells Theranostics. 2024 Oct 21;14(18):6947-6968.
HUVEC cells 5 μM 8 hours Validate the anti-ferroptotic effect of Dipyridamole in pulmonary endothelial cells Theranostics. 2024 Oct 21;14(18):6947-6968.
A549 cells 10 μM 8 hours Screening FDA-approved drug library to identify Dipyridamole as an effective ferroptosis inhibitor Theranostics. 2024 Oct 21;14(18):6947-6968.
Neutrophils 10 µM 3 hours Dipyridamole suppresses APS IgG-mediated NETosis via activation of the adenosine A2A receptor Nat Commun. 2019 Apr 23;10(1):1916.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Bilateral cavernous nerve crush (BCNC) model Oral 40 mg/kg Once daily for 4 weeks To evaluate the therapeutic effects of Dipyridamole on BCNC model rats, it was found that 40 mg/kg Dipyridamole significantly increased penile adenosine levels, improved erectile function, and down-regulated the expression of HIF-1α and TGF-β. Adv Sci (Weinh). 2024 Aug;11(30):e2306514.
C57BL/6J mice LPS-induced acute lung injury model Intraperitoneal injection 10 mg/kg Pretreatment 1 hour before, lasting for 24 hours Validate the in vivo anti-ferroptotic and therapeutic effects of Dipyridamole in alleviating lung injury Theranostics. 2024 Oct 21;14(18):6947-6968.
Athymic male mice Du145 subcutaneous tumor model Intraperitoneal injection 40 mg/kg/injection 14 consecutive days, once daily To evaluate the antitumor efficacy of G47Δ enhanced by DP and DL Cancer Res. 2010 May 15;70(10):3890-5
Mice Venous thrombosis model Intraperitoneal injection 5 mg/kg Started one day before surgery and continued through the experiment Dipyridamole mitigates venous thrombosis by suppressing NETosis Nat Commun. 2019 Apr 23;10(1):1916.
Mice Partial liver ischemia model Intravenous injection 0.5mg/25g mouse IV Single dose, 15 minutes prior Mice pretreated with dipyridamole showed elevated hepatic adenosine levels, reduced plasma AST and ALT levels, and attenuated hepatic tissue injury after liver ischemia and reperfusion. Hepatology. 2013 Nov;58(5):1766-78
C57BL/6J mice Chronic hindlimb ischemia model Oral 200 mg/kg Twice daily, starting 3 days prior to ischemia induction and continued throughout the study Dipyridamole significantly enhances ischemia-induced arteriogenesis through a PKA-dependent eNOS pathway, rapidly restoring ischemic hindlimb blood flow, increasing vascular density and cell proliferation. Cardiovasc Res. 2010 Mar 1;85(4):661-70

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.98mL

0.40mL

0.20mL

9.91mL

1.98mL

0.99mL

19.82mL

3.96mL

1.98mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Klabunde RE. Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol. 1983 Sep 16;93(1-2):21-6.

[2]Best LC, McGuire MB, et al. Mode of action of dipyridamole on human platelets. Thromb Res. 1979;16(3-4):367-79.

[3]Glass WF 2nd, Moore JB Jr. Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors. Biochem Pharmacol. 1979 Apr 1;28(7):1107-12. doi: 10.1016/0006-2952(79)90313-7. PMID: 87197.

[4]FitzGerald GA. Dipyridamole. N Engl J Med. 1987 May 14;316(20):1247-57. doi: 10.1056/NEJM198705143162005. PMID: 3553945.

[5]Dawicki DD, Agarwal KC, Parks RE Jr. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233. Thromb Res. 1986 Jul 15;43(2):161-75. doi: 10.1016/0049-3848(86)90057-5. PMID: 3016942.

[6]Clarke WR, Uezono S, Chambers A, Doepfner P. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm Pharmacol. 1994 Apr;7(2):81-9. doi: 10.1006/pulp.1994.1009. PMID: 8081075.

[7]Dukarm RC, Morin FC 3rd, Russell JA, Steinhorn RH. Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension. Pediatr Res. 1998 Dec;44(6):831-7. doi: 10.1203/00006450-199812000-00002. PMID: 9853914.

[8]Lichtner R, Wedderburn N. Enhancement of the immune response to sheep erythrocytes in mice by phosphodiesterase-inhibiting dipyridamole derivatives. J Immunopharmacol. 1984;6(1-2):43-55. doi: 10.3109/08923978409026457. PMID: 6088639.

 

Historical Records

Categories